OIS Podcast | Ophthalmology's leading Podcast Nanoscope is Bypassing Dying Photoreceptors With Bipolar Cells Episode discussion: Nanoscope Therapeutics COO Paul Hallen discusses Mogenry's bipolar cell bypass mechanism and launch readiness.
Speakers’ claims: Paul Hallen, COO of Nanoscope Therapeutics, joins the OIS Podcast to discuss Mogenry, a gene therapy that bypasses damaged photoreceptors by using an AAV vector to express opsins in intact bipolar cells. He notes that peak vision improvement occurs over five to six months, with sustained improvement of up to three lines of vision over three years. Hallen highlights the therapy's safety profile, citing zero Serious Adverse Events in the Remains study, and its applicability across 300+ genetic variants of Retinitis Pigmentosa as well as Stargardt's and Dry AMD. He emphasizes the operational complexity of the deep cold chain required for delivery and the importance of pre-secured reimbursement approvals for a successful launch.
Gene Therapy Ophthalmology Retinitis Pigmentosa
Nov 13, 2026 6 min 0 assets 10 claims to verify